close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,078.00 -7.19 (-0.66%)
Streaming Delayed Price Updated: 12:24 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
News headline image
This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today? ↗
Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop... 
Via Stocktwits
News headline image
2 Growth Stocks That Could Be Worth $1 Trillion in 5 Years ↗
These two longtime market leaders should continue to perform well. 
Via The Motley Fool
News headline image
Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure ↗
Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment. 
Via Investor's Business Daily
News headline image
The Invesco QQQ Trust Has a Glaring Flaw by Excluding This "Ten Titans" Stock and 3 Other Megacap Growth Stocks. Here's an ETF That Corrects the Error. ↗
Investors looking for top growth stocks on the Nasdaq and NYSE may want to consider alternatives to the Invesco QQQ. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
Eli Lilly’s Weight-Loss Star Mounjaro Paused In UK Until September Ahead Of Massive Price Jump ↗
Via Stocktwits
News headline image
Analyst Expectations For Eli Lilly's Future ↗
 
Via Benzinga
Eli Lilly’s Oral Drug Delivers Significant Weight Loss In Late-Stage Study ↗
Via Stocktwits
News headline image
UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears ↗
Patients in UK struggle to obtain Mounjaro drug due to high demand, sharp price increase. Shortages causing stress and health risks. 
Via Benzinga
News headline image
Stevens Capital Closes Out Position in Eli Lilly ↗
Via The Motley Fool
News headline image
2 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade ↗
It doesn't take much to get your money to start working for you on Wall Street. 
Via The Motley Fool
News headline image
Market Movers: Unpacking the Forces Behind Recent Stock Swings
The financial markets have been a dynamic arena recently, showcasing significant and often dramatic movements in individual stock valuations. These shifts are not random but are deeply rooted in... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
The Phoenix Market: How Wall Street Defied the "Trump Slump" to Soar to New Highs
The year 2025 has etched itself into financial history as a testament to the stock market's extraordinary resilience. After a tumultuous April and May, dubbed the "Trump Slump," which saw significant... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
Veeva Makes A Bearish Move On One Pockmark In Its Quarterly Report ↗
The company beat second-quarter expectations, with the exception of one key metric. 
Via Investor's Business Daily
News headline image
MongoDB To Rally Around 63%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
New Eli Lilly Data Puts Verzenio In Breast Cancer Spotlight ↗
Eli Lilly's Phase 3 trial shows Verzenio improves survival in high-risk early breast cancer, with Q2 revenue up 12% to $1.49 billion. 
Via Benzinga
News headline image
Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk) ↗
Druckenmiller's Duquesne Family Office just scooped up a popular weight-loss stock. 
Via The Motley Fool
Topics Economy World Trade
News headline image
Why Novo Nordisk Stock Tumbled on Tuesday ↗
A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy. 
Via The Motley Fool
News headline image
Why Eli Lilly Stock Trounced the Market on Tuesday ↗
The pharma giant advanced a medication that could be extremely competitive in a high-profile segment. 
Via The Motley Fool
News headline image
Russell 2000 Hits 9-Month Highs, Bitcoin Drops Below $110,000: What's Moving Markets Tuesday? ↗
Investors are watching small caps heat up on an otherwise slow Tuesday morning, with the Russell 2000 climbing 1% and outpacing its larger peers, amid growing bets on a Fed rate cut next month. 
Via Benzinga
Topics Economy
EchoStar, Energy Fuels, Eli Lilly, Hut 8, Nio: Stocks Making The Biggest Moves Today ↗
Via Stocktwits
News headline image
Eli Lilly Stock Jumps On Weight-Loss Pill Trial ↗
Eli Lilly stock dropped more than 20% due to underwhelming results from its drug trials. However, a rebound may be underway. 
Via Benzinga
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
News headline image
Rep. Jonathan Jackson Has Bought Up to $390K Worth Of Amazon.com Stock: Here's What You Should Know ↗
 
Via Benzinga
News headline image
As the Market Rotates, This Healthcare ETF Is Leading the Way ↗
Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure. 
Via MarketBeat
Topics ETFs
News headline image
Eli Lilly Scores Another Weight-Loss Win; Viking, Novo Stocks Slump ↗
Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful test. 
Via Investor's Business Daily
News headline image
Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors ↗
Eli Lilly's Phase 3 trial of orforglipron showed significant weight loss, blood sugar control, and improved heart health markers in adults with diabetes. 
Via Benzinga
News headline image
Viking Therapeutics: What's Next? ↗
Viking's 40% crash over fixable dosing issues ignores its best-in-class 12.2% oral weight loss and Phase 3 momentum. 
Via The Motley Fool
News headline image
The Great Rebalancing: Sector Rotation Signals a Shifting Market Landscape
The stock market is currently undergoing a significant rebalancing act, as investors strategically shift their capital from one sector to another in anticipation of evolving economic conditions. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
When AI Execs Say the Market Looks Bubbly ↗
Market chatter about the frothiness of the AI market seems to be picking up as OpenAI CEO Sam Altman claims that he too sees a bubble forming. 
Via The Motley Fool
Topics Artificial Intelligence
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today